EDX110 Randomized Control Trial for Treatment of DFUs
Active, not recruiting · Not applicable · NCT07209358
Conditions: Wound Heal, Diabetic Foot Ulcer
At a glance
- Research payments reported, 2025
- $221,104
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 300
About the trial
- Sponsor
- ConvaTec Inc.
- Tested
- EDX110 (device)
- Dates
- Started 2025-10-30; completion 2027-06-30
- Results posted
- Not yet
Prospective, multi-centered, observer blinded, pre-market study, 1:1 randomized control trial, to determine if addition of EDX110 dressing system to standard of care leads to an improvement in diabetic foot ulcers healing compared to just using standard of care.
From ClinicalTrials.gov, last updated 2026-11-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Convatec Inc. reported $221,104 in research payments for this study in 2025 (5 payments).
Products named: Aquacel Ag+
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jaminelli L. Banks, DPM Podiatrists · Phoenix, AZ
- Stanley K. Mathis, D.P.M. Podiatrists · Los Angeles, CA
- Joseph M. Caporusso, DPM PA Podiatrists · Mcallen, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clemente Clinical Research $122,280
- Advanced Footcare LLC $79,225
- Futuro Clinical Trials LLC $19,600
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.